Description：Avatrombopag maleate is a thrombopoietin receptor agonist used in adult patients with chronic liver disease (CLD) who suffer from thrombocytopenia and plan to undergo medical or dental surgery., The new drug was first developed by Japan's Antailai Pharmaceutical Group, and after several authorizations, it was finally developed by AkaRx Pharmaceutical Company, a subsidiary of Dova Pharmaceutical Company in the United States. The new drug was applied for marketing to the US Food and Drug Administration (FDA) and was approved for marketing on May 21, 2018.